Skip to content

Role of dexmedetomidine as an add on drug in serratus anterior muscle block in breast surgery

Role of dexmedetomidine as an adjuvant in serrates anterior muscle block - A randomised Control Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/011736
Enrollment
60
Registered
2018-02-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: null- Patients suffering from carcinoma breast scheduled to undergo modified radical mastectomy (MRM), with ASA status 1-2.

Interventions

Intervention1: Serratus Anterior Muscle block with the adjuvant (dexmedetomidine): Interventional group to receive serrates anterior muscle block with local anaesthetic (0.25% ropicvacaine) 18 ml alon

Sponsors

Government Medical College and Hospital Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Females diagnosed with carcinoma breast. 2. American Society of Anesthesiologists physical status I-II 3. Age 18-80 years.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. History of relevant drug allergy. 2. History of psychiatric illness, substance abuse. 3. Severe cardiovascular, respiratory, liver diseases, metabolic or neurological disease. 4. Chronic treatment with analgesics. • Pregnancy. • Coagulopathy. • Infection at planned injection site. • Psychological inability of the patient to understand visual analogue scale.

Design outcomes

Primary

MeasureTime frame
To calculate and compare cumulative morphine consumption over 24 hours in patients receiving serratus anterior muscle block with and without dexmedetomidine.Timepoint: Patient will be monitored for haemodynamic variables and these recordings will be assessed at 30mins, 1hr, 4hrs, 8hrs, 12hrs and 24hrs. Simultaneously, at these time intervals the pain will also be assessed using VAS score which will be evaluated both at rest and on movement.

Secondary

MeasureTime frame
To monitor and compare reduction in pain intensity, to compare the dose of total anti emetics, to monitor haemodynamic variables and to note side effects of the procedure/drugs in use all for 24hrs.Timepoint: Patient monitored for haemodynamic variables along with pain at rest and on movement, assessed at 30mins, 1hr, 4hr, 8hr, 12hr, 24hr

Countries

India

Contacts

Public ContactDr Satinder Gombar

Government Medical College and Hospital, Chandigarh

dr_sgombar@rediffmail.com9646121520

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026